Postpartum coordinated handoff: from MFM back to the medical home.

Background

The patient (placeholder name S.) is 34 and was established in our adult primary-care panel for four years prior to this episode. Past medical history: chronic hypertension (diagnosed in 2022), polycystic ovarian syndrome, prior miscarriage at 9 weeks (2023). Preconception counseling at this practice in late 2024 included a switch from lisinopril to labetalol prior to conception, baseline ophthalmologic and renal evaluation, and a planned pregnancy.

S. conceived in January 2025. Prenatal coordination at this practice ran from 6 weeks through 26 weeks. At a 24-week visit a 1-hour glucose challenge returned 168 (cutoff 140); the 3-hour confirmed gestational diabetes (per ACOG diagnostic criteria). With chronic hypertension and now GDM, this met our internal criterion for MFM co-management; we transitioned to MidHudson Regional Maternal-Fetal Medicine at 26 weeks (slightly earlier than our usual 28-week handoff), with a written summary and a personal phone call from Dr. Voorhies to the receiving MFM clinician.

Decision points

1. Handoff to MFM

The handoff package included: a full prenatal record summary; the home BP log (averaging 138/86 on labetalol 200 mg twice daily); the OGTT result and the GDM management plan we had begun (carbohydrate-counting nutrition counseling at Hudson Valley Nutrition); and S.'s specific preferences regarding birth plan. We continued to be reachable for non-MFM issues during the MFM-led period.

2. Delivery and immediate postpartum

S. delivered at MidHudson Regional at 38+3 weeks, induced for elevated BP and stable GDM. The delivery was uncomplicated; the infant weighed 3,440 g, Apgar 8/9. S. was discharged on day 2 on labetalol 200 mg three times daily and a glucose check schedule. The discharge summary was sent to us electronically and was in the chart on day 3.

3. Postpartum return at week 4

S. returned for the postpartum primary-care visit at week 4 (CCH-004-PP, 60 minutes). Findings: BP 142/90 at the visit, home log averaging 144/92; weight up 3 kg from pre-pregnancy (after losing 9 kg post-delivery); EPDS (Edinburgh Postnatal Depression Scale) 14 (moderate, with positive response to item 10). Glucose was normal at 4 weeks post-partum (random 92, fasting 94 the next morning).

The decisions made at this visit:

• Hypertension recalibration. Labetalol 200 mg three times daily continued; we added amlodipine 5 mg in the evening for diurnal coverage. Plan to recheck in 2 weeks.
• Postpartum depression evaluation. Salim Okonkwo, PMHNP-BC, was paged into the visit (he was in the building) for a brief joint evaluation. He scheduled a CCH-003 new-evaluation visit for the following week and discussed sertraline initiation. S. preferred to begin with weekly therapy plus a four-week trial period before medication; the plan was documented; safety plan completed using Stanley-Brown.
• Contraceptive plan. S. wanted a Mirena IUC and would return for placement at the 6-week visit. Bridging contraception with progestin-only pills in the meantime; lactation discussion held.
• Lactation support. Helena Rey was paged in to assess latch and weight-gain trajectory; she scheduled two follow-up lactation visits at no extra charge as part of the standard CCH-002 newborn schedule.

4. The four-week therapy trial and the medication decision

At the 4-week post-postpartum-visit follow-up, EPDS had risen to 17 despite weekly therapy. S. now wanted to begin sertraline. Sertraline 50 mg started, with an explicit plan to titrate to 100 in 2 weeks; MotherToBaby sertraline-and-breastfeeding fact sheet given.

Outcome

At week 26 postpartum (the end of this case-log period): BP 122/78 averaged over 2 weeks; on amlodipine 5 mg, with labetalol now off (tapered over 8 weeks); EPDS 5 (low); breastfeeding successfully; Mirena placed at week 8; infant on the standard Bright Futures schedule with Helena Rey; S. is back at her job (graphic designer at a Kingston design studio) at 24 hours/week. We will see her at her annual visit in March 2026; her infant will be seen at the 6-month visit.

What we got wrong

We could have screened for postpartum depression at the 2-week visit rather than the 4-week visit. ACOG 2023 Clinical Practice Guideline on screening for mental health conditions during pregnancy and postpartum recommends screening at the 2–4 week postpartum encounter; we had been defaulting to the 4-week visit. We changed the workflow on 2025-12-01: every postpartum patient now receives an EPDS at the 2-week post-discharge phone call, before the in-person visit.